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Abstract: AMP-activated protein kinase (AMPK) is a pivotal regulator of metabolism at the 
cellular and organismal level. A growing body of evidence also supports an important role for 
AMPK in suppressing inflammation but the molecular mechanisms responsible remain unclear. 
Here we demonstrate that AMPK rapidly inhibits activation of the JAK-STAT pathway and its 
downstream sequelae by an IL-6 trans-signaling complex. In vitro kinase assays show that 
AMPK can directly phosphorylate two residues (Ser515, Ser518) within the JAK1 SH2 domain. 
AMPK activation enhances JAK1interaction with 14-3-3 proteins in vitro, an effect which 
requires Ser515 and Ser518 and is abolished in cells lacking AMPK activity. Furthermore, 
mutation of Ser515 and Ser518 abolishes the ability of AMPK to inhibit JAK-STAT signaling 
stimulated by an IL-6 trans-signaling complex or following expression of a constitutively active 
Val658Phe-mutated JAK1. Importantly, clinically utilized AMPK activators metformin and 
salicylate enhance endogenous JAK1 phosphorylation and inhibit STAT3 phosphorylation in 
primary vascular endothelial cells. Therefore our findings reveal a previously unappreciated 
mechanism by which JAK1 function can be directly regulated in response to metabolic stress and 
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provide a mechanistic rationale for potential utilization of AMPK activators in a range of 
diseases associated with enhanced activation of the JAK-STAT pathway. 
Introduction 
The Janus kinase–signal transducer and activator of transcription (JAK–STAT) pathway is 
utilized by a range of cytokines that control survival, proliferation and differentiation responses 
in diverse cell types. JAKs comprise a family of four cytoplasmic tyrosine kinases (JAK1-JAK3, 
Tyk2) that function as essential signaling components immediately downstream of receptors for 
many hematopoietic cytokines, such as granulocyte-macrophage colony-stimulating factor, 
erythropoietin, leptin, interferons (IFNs) and interleukins such as IL-6 (1)(2). The IL-6 receptor 
comprises two distinct subunits, an IL-6-binding protein (IL-6R) and a 130 kDa signal-
transducing subunit (gp130) which is shared by all IL-6-family cytokines (2). The gp130 subunit 
is ubiquitously expressed while IL-6R expression is restricted to hepatocytes, monocytes, 
neutrophils and some B and T cell subsets. However, IL-6 can also bind to a soluble form of the 
receptor (sIL-6R) generated either by limited proteolytic cleavage of membrane-bound IL-6Rα 
or alternate splicing of IL-6R primary transcripts. The resulting sIL-6R/IL-6 “trans-signaling” 
complexes can then associate with gp130 on cells that do not express the membrane-bound IL-
6R, thereby widening the spectrum of IL-6-responsive cells (3). 
IL-6 binding to the receptor complex results in the activation of gp130-bound JAKs. The 
activated JAKs are then able to phosphorylate specific Tyr residues within the receptor’s 
cytoplasmic domain, which serve as docking sites for SH2 domain-containing proteins. The 
major intracellular mediators are the signal transducer and activator of transcription (STAT) 
proteins. IL-6 is capable of activating STAT1 and STAT3, although STAT3 activation has been 
observed to a greater extent than STAT1. Activation of STATs require their recruitment to 
specific JAK-phosphorylated Tyr residues on gp130 via their SH2 domain followed by JAK-
mediated phosphorylation of a Tyr residue in the transactivation domain (Tyr705 on STAT3, 
Tyr701 on STAT1). Tyr-phosphorylated STATs then form dimers which can translocate to the 
nucleus to activate target gene transcription. IL-6 can also activate the extracellular signal-
regulated kinase 1,2 (ERK1,2) and phosphatidylinositol 3-kinase pathways following recruitment 
of the Tyr phosphatase SHP2 to JAK-phosphorylated gp130 (2)(4). 
AMP-activated protein kinase (AMPK) is the highly conserved downstream component of a 
Ser/Thr protein kinase cascade involved in the regulation of metabolism. It was initially 
characterised as a Ser/Thr protein kinase allosterically activated by increases in intracellular 
AMP levels resulting from the decline in intracellular ATP that occurs following nutrient 
deprivation or hypoxia (5)(6). AMPK is a heterotrimeric complex comprised of a catalytic  
subunit and regulatory  and  subunits. In mammals, isoforms of each subunit (1, 2, 1, 2, 
1, 2, 3) are encoded by seven genes. The  subunits are each N-terminally myristoylated, 
contain carbohydrate-binding domains and interact with both the  and  subunits, whereas the  
subunits contain the AMP/ADP binding sites responsible for sensing cellular energy status 
[reviewed in (5)]. In addition to the allosteric activation of AMPK by adenine nucleotides, AMP 
or ADP binding to the regulatory  subunit of AMPK promotes phosphorylation of the catalytic 
 subunit at Thr172, which is required for AMPK activity. Binding of AMP and ADP also 
inhibits dephosphorylation of AMPK, maintaining Thr172 phosphorylation by the upstream 
AMPK Thr172 kinase, liver kinase B1 (LKB1) (5)(6). In the absence of changes in adenine 
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nucleotide ratios, AMPK can be activated by increases in intracellular Ca2+ concentrations in 
cells expressing Ca2+/calmodulin-dependent protein kinase kinase  (CaMKK) (5)(6). 
The most studied aspect of AMPK function is its role in maintaining cellular energy stores and 
regulating whole body energy balance. An important aspect of this role is the direct 
phosphorylation of metabolic enzymes such as acetyl coA carboxylase (ACC) 1 and 2, which 
catalyze the carboxylation of acetyl coA to malonyl-CoA, a key substrate for fatty acid 
biosynthesis that also inhibits free fatty acid transport into mitochondria (7). AMPK-mediated 
phosphorylation of ACC1 on Ser79 inhibits its activity thereby suppressing fatty acid synthesis 
and enhancing -oxidation (8). An increasing body of evidence has revealed that AMPK is also 
an important regulator of inflammatory responses. For example, AMPK-dependent inhibition of 
tumor necrosis factor TNF-, lipopolysaccharide (LPS)- and interleukin-1IL-1-
stimulated leukocyte recruitment to vascular endothelial cells in vitro has been observed in 
multiple studies, and is associated with reduced induction of adhesion molecules (e.g. VCAM-1 
and E-selectin) and chemokines (e.g. CCL2 and CCL3) (9)(10). Studies using AMPK1-/- and 
AMPK2-/- mice suggest that both isoforms can contribute to inhibition of post-ischemic 
leukocyte adhesion to blood vessels in vivo by the AMPK activator 5’-aminoimidazole-4-
carboxamide ribonucleoside (AICAR) (11). Consistent with a role for AMPK in suppressing 
inflammation in vivo, aortae from AMPK1-/- mice have been shown to display enhanced 
angiotensin II-stimulated VCAM-1 expression (12). Activation of AMPK with AICAR is also 
associated with reduced infiltration of inflammatory cells in rodent models of acute and chronic 
colitis (13), lung injury (14) and autoimmune encephalomyelitis (15). Furthermore, increased 
infiltration and activation of macrophages have been observed in adipose tissue from wild type 
mice transplanted with bone marrow from AMPK1-/- mice (16). Therefore, taken as a whole, it 
has become clear that AMPK can limit inflammatory cell infiltration and activation in multiple 
settings.  
While AMPK’s ability to maintain fatty acid oxidation in macrophages has been proposed as an 
important mechanism by which it limits inflammation in macrophages (16), several mechanisms 
have also been identified though which AMPK can directly inhibit pro-inflammatory signaling 
pathways. However, while several potential mechanisms have been proposed to explain AMPK-
mediated inhibition of the NF-B pathway in response to stimuli such as TNF, LPS and IL-1 
(9)(17), relatively few studies have examined how the JAK-STAT pathway is controlled by 
AMPK. This is a particularly important issue to address given the pathological roles of enhanced 
JAK-STAT signaling in multiple chronic inflammatory conditions such as atherosclerosis, colitis 
and rheumatoid arthritis, as well as several cancers and hematological disorders driven by 
mutational activation of JAK isoforms (1)(18)(19)(20). 
In this study, we demonstrate that AMPK can rapidly and profoundly inhibit activation of the 
JAK-STAT pathway in response to multiple stimuli. In addition, we show that this occurs via a 
previously unappreciated mechanism involving direct AMPK-mediated phosphorylation of 
JAK1 within its regulatory SH2 domain. Our data therefore reveal how metabolic stress can 
rapidly control signaling from JAK1, and provide a molecular basis for potential repurposing of 
AMPK activators for a range of diseases associated with enhanced activation of the JAK-STAT 
pathway. 
Results 
AMPK rapidly inhibits IL-6 signaling and function 
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AMPK plays a largely protective role in vascular endothelial cells (ECs) via both NO-dependent 
and –independent mechanisms (21)(22). Incubation of human umbilical vein ECs (HUVECs) 
with sIL-6R/IL-6 trans-signaling complexes for 30 min significantly increased STAT3 
phosphorylation on Tyr705, an effect that was significantly inhibited in HUVECs that had been 
pre-incubated with distinct stimuli that each activate AMPK as determined by assessing ACC1 
phosphorylation on Ser79 (8): these were AICAR, which is phosphorylated intracellularly to the 
AMP mimetic ZMP (23), A769662, which binds and activates 1-containing AMPK complexes 
via an AMP/ADP-independent mechanism (24), and a combination of clinically utilized AMPK 
activators metformin and salicylate, which synergistically activate AMPK via elevation of 
cellular AMP levels and directly binding 1-subunits respectively (25)(26)(27) (Figure 1A). 
Under these conditions, AMPK activation on its own had no detectable effect on STAT3 
phosphorylation. Targeted short inhibitory RNA (siRNA)-mediated knockdown of AMPK1 
catalytic subunits reduced the inhibitory effects of both A769662 (Figure 1B) and AICAR 
(Figure S1), indicating that these effects were mediated via AMPK activation. In addition, 
adenovirus (AV)-mediated expression of a catalytically inactive dominant negative (DN) 
AMPK1 subunit in which Asp157 located within subdomain VII of the catalytic domain is 
mutated to Ala (28) was sufficient to block A769662-mediated inhibition of STAT3 
phosphorylation in HUVECs versus a GFP-expressing control AV (Figure S1). Together, these 
data demonstrated that activation of AMPK by multiple stimuli triggered a rapid and significant 
reduction in the ability of sIL-6R/IL-6 to stimulate STAT3 phosphorylation on Tyr705. 
To assess the functional consequences of AMPK-mediated inhibition of IL-6 signaling, we 
initially examined the effect of A769662 on IL-6-mediated induction of STAT3 target genes 
suppressor of cytokine signaling 3 (SOCS3) and CCAAT/enhancer binding protein  (C/EBP) 
(29)(30). Similar to the effect on STAT3 phosphorylation, A769662 significantly inhibited sIL-
6R/IL-6-stimulated accumulation of SOCS3 and C/EBP protein (Figure 1C) and mRNA 
(Figure S2). In addition, we took advantage of the well described ability of IL-6 to induce 
chemokine expression and thereby increase monocyte chemotaxis (20)(31)(32). Conditioned 
media was collected from HUVECs subsequent to stimulation in the presence or absence of 
A769662 and/or sIL-6R/IL-6 prior to assessment of its capacity to stimulate monocyte 
migration using a trans-well migration assay. Since the HUVECs were extensively washed to 
remove A769662 and sIL-6R/IL-6 prior to collection of conditioned medium, these had no 
effect on migration directly. It was found that the migration of U937 monocytic cells towards 
conditioned media from sIL-6R/IL-6-stimulated HUVECs was significantly increased. 
Conditioned medium from HUVECs pre-incubated with A769662 for 30 min prior to cytokine 
stimulation elicited significantly less U937 cell migration compared to conditioned media from 
sIL-6R/IL-6-stimulated HUVECs (Figure 1D). 
AMPK inhibits signaling from multiple cytokine receptor complexes 
To identify the point in the IL-6 signaling pathway at which AMPK was acting, we examined 
signaling downstream of multiple cytokines other cytokine receptors. Importantly, we found that 
the inhibitory effect of AMPK on sIL-6R/IL-6 responses was not restricted to STAT3, as pre-
incubation of HUVECs with A769662 also abrogated sIL-6R/IL-6-stimulated phosphorylation 
of STAT1 on Tyr701 (Figure 2A). While IL-6 signals downstream via interaction with either a 
membrane-bound or sIL-R and gp130 homodimers, leukemia inhibitory factor (LIF) and 
oncostatin M (OSM) signal via cytokine interaction with gp130/LIF receptor (LIFR) and OSM 
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receptor/gp130 heterodimers respectively (2)  Similar to sIL-6R/IL-6, pre-treatment of 
HUVECs with A769662 significantly reduced OSM- and LIF-stimulated STAT3 and STAT1 
phosphorylation (Figure 2A). In addition, the ability of each cytokine to stimulate STAT3 
phosphorylation on Ser727, which is critical for full transcriptional activation and is mediated by 
cytokine receptor activation of either ERK1,2 or phosphatidylinositol 3-kinase/mammalian target 
of rapamycin (mTOR) pathways, was similarly reduced by A769662 (Figure 2A). In support of a 
post-receptor effect of AMPK, A769662 also suppressed STAT3 phosphorylation in response to 
IFN, which activates STATs via a distinct IFN receptor 1 (IFNAR1)/IFNAR2 complex that 
lacks gp130 (33) (Figure 2B). Taken together, these results would suggest that AMPK exerts its 
inhibitory effects on multiple cytokine-activated signaling pathways at one or more common loci 
downstream of both IFNAR1/IFNAR2 and gp130-containing cytokine receptor complexes. 
JAK1 is phosphorylated by AMPK in vitro 
The IFNAR1/IFNAR2 complex couples to STATs via JAK1 and Tyk2 (33)(34). We performed 
JAK1, JAK2 and Tyk2 siRNA knockdown experiments in HUVECs which demonstrated that 
JAK1 accounts for most of the ability of sIL-6R/IL-6 complexes to activate STAT3 (Figure 
S3). Thus JAK1 was identified as a potential common AMPK-regulated post-receptor target. As 
AMPK is a Ser/Thr protein kinase, and the inhibitory effect of AMPK activator A769662 
occurred rapidly, we investigated the possibility that AMPK could directly phosphorylate JAK1. 
Peptide arrays of overlapping 25-mer peptides sequentially shifted by five amino acids and 
spanning the full human JAK1 open reading frame (residues 1-1154) were utilized for in vitro 
kinase assays with AMPK purified from rat liver and [32P]ATP (35)(36). These experiments 
identified a sequence within the JAK1 SH2 domain (R506YSLHGSDRSFPSLGDLMSHLKKQI) 
as a potential substrate whose phosphorylation on the array was greater than that of the so-called 
“SAMS” peptide typically used as an in vitro substrate for assay of AMPK activity and which is 
based on the primary Ser79 AMPK phosphorylation site on rat ACC1 (35) (Figure 3A). To 
define which of the five potential phospho-acceptor sites within the JAK1 peptide were 
phosphorylated in vitro by AMPK, kinase assays were then performed on additional arrays 
containing the wild type (WT) peptide sequence and mutant peptides in which each Ser residue 
was replaced with a non-phosphorylatable Ala residue either individually or in combination 
(Figure 3B). Simultaneous replacement of all five Ser residues with Ala abolished AMPK-
mediated phosphorylation of the peptide. Individual replacement of each Ser residue with Ala 
either did not alter or enhanced AMPK phosphorylation of the resulting peptides. However, 
simultaneous replacement of Ser515 and Ser518 with Ala abrogated peptide phosphorylation to 
the same extent as mutating all five Ser residues. In addition, a peptide in which Ser508, Ser512 
and Ser524 were all replaced with Ala was phosphorylated to the same extent as the WT JAK1 
sequence (Figure 3B). Taken together, these observations identified Ser515 and Ser518 in human 
JAK1 as potential sites of phosphorylation by AMPK in vitro. 
Peptide library screening, mutagenesis and molecular modelling studies (37)(38) have all been 
used to identify optimal AMPK substrate motifs. Bioinformatic analysis of JAK1 orthologues 
revealed that phosphorylation sites equivalent to Ser518 in human JAK1 are conserved in 
multiple species (Figure 3C). Importantly, residues at positions +3 and +4 downstream of the 
phospho-acceptor sites which are known to be critical for substrate recognition are also well 
conserved (Figure 3C). Interestingly, Ser518 is located at the start of a specific -helix 
conserved amongst all JAK isoforms (Figure 3D) (39–41). In contrast, Ser515 is unique to 
human JAK1 and would only form a weak consensus for AMPK substrate recognition if Ser518 
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became negatively charged via prior phosphorylation (Figure 3C). However other examples of 
AMPK substrates that only loosely follow the optimized consensus have also been documented 
(e.g. eNOS phosphorylation at Ser633 (42)). Thus we examined a potential role for both Ser515 
and Ser518 in more detail. 
AMPK-mediated phosphorylation of JAK1 in intact cells 
A common mechanism for phosphorylation-mediated regulation of target protein function is 
phosphorylation-dependent binding to members of the 14-3-3 family of proteins (43). To assess 
whether phosphorylation of Ser515 and Ser518 could facilitate JAK1 interaction with 14-3-3 
proteins in vitro, overlay assays were performed with horseradish peroxidase (HRP)-conjugated 
14-3-3 (HRP-14-3-3)and peptide arrays comprising 25-mer peptides from the identified JAK1 
region in which either or both of Ser515 and Ser518 were phosphorylated (Figure 4A). These 
demonstrated that phospho-Ser515 and phospho-Ser518 peptides strongly interacted with HRP-
14-3-3 in vitro, while no binding was detectable with either non-phosphorylated peptide or 
peptide in which both Ser515 and Ser518 were phosphorylated (Figure 4A). 
A phosphorylation-dependent interaction with 14-3-3 proteins has been reported for several 
AMPK substrates, including Atg9, Raptor and ULK1 (44)(38)(45). We tested our ability to 
detect any such interaction using two approaches. Firstly, we compared the ability of bacterially 
expressed and affinity purified GST/14-3-3 fusion proteins to capture AMPK-phosphorylated 
JAK1 in pull down assays from soluble extracts prepared from intact cells. Initial experiments in 
JAK1-null U4C human fibrosarcoma cells stably expressing recombinant JAK1 (46)(47) 
demonstrated that distinct GST/14-3-3 isoforms (14-3-3 and 14-3-3) but not GST alone could 
specifically isolate JAK1 (Figure S4). To assess the importance of Ser515 and Ser518 in 
mediating this interaction, we used a different approach in which WT and Ser515,518Ala 
(SSAA)-mutated human JAK1 were transiently expressed in U4C cells prior to 
immunoprecipitation of JAK1 and overlay of blots with HRP-14-3-3. Consistent with the 
peptide array overlays, these experiments demonstrated that while WT JAK1 could be 
specifically identified, the SSAA-mutated JAK1 could not despite equivalent levels of JAK1 in 
the immunoprecipitates (Figure S4). Finally, to assess the role of AMPK activation on JAK1 
phosphorylation in intact cells, WT and Ser515,518Ala (SSAA)-mutated human JAK1 were 
transiently expressed in U4C cells prior to treatment with A769662 and preparation of cell 
extracts for pull down assays with GST/14-3-3 and immunoblotting with anti-JAK1 antibody 
(Figure 4B). These demonstrated that A769662 treatment increased 14-3-3 interaction with 
JAK1 but not Ser515,518Ala (SSAA)-mutated JAK1 despite equivalent activation of AMPK and 
expression of WT and mutated JAK1 proteins in transfected cells (Figure 4B). 
To further examine the AMPK dependence of this effect, GST/14-3-3 pull downs were 
performed in WT murine embryonic fibroblasts (MEFs) and MEFs with no detectable AMPK 
activity due to homozygous deletion of AMPK1 and 2 catalytic subunits (48). AMPK 
activation with A769662 in WT MEFs transiently increased interaction of endogenous JAK1 
with GST/14-3-3 but this effect was absent in cells devoid of AMPK activity as determined by 
the loss of ACC phosphorylation on Ser79 (Figure 4C). As murine JAK1 lacks Ser515 or an 
equivalent residue (Figure 3C), this suggests that phosphorylation of Ser517 alone on murine 
JAK1 is required for interaction with GST/14-3-3. Finally, we examined the effects of 
combined metformin and salicylate treatment on AMPK-mediated JAK1 phosphorylation (as 
determined by interaction with GST/14-3-3) in HUVECs, a treatment which we had already 
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shown significantly inhibited sIL-6R/IL-6-stimulated STAT3 phosphorylation (Figure 1A). 
Combined treatment of HUVECs with metformin and salicylate significantly increased ACC 
phosphorylation and triggered a transient increase in endogenous JAK1 captured by GST/14-3-
3 which peaked at 1 hr post-stimulation (Figure 4D). 
AMPK-mediated inhibition of JAK1-dependent signaling requires Ser515 and Ser518 
To investigate any contribution of AMPK-mediated JAK1 phosphorylation on Ser515 and 
Ser518 towards regulating signaling, we utilized JAK1-null U4C human fibrosarcoma cells. 
Consistent with previous work (46) and our own siRNA experiments in HUVECs, loss of JAK1 
was associated with no detectable sIL-R/IL-6-mediated phosphorylation of STAT3. However, 
transient expression of WT human JAK1 was able to restore sIL-R/IL-6-mediated STAT3 
phosphorylation over GFP-expressing controls and this was inhibited by pre-treatment with 
A769662 similar to the phenomenon observed in HUVECs (Figure 5A). Expression of SSAA-
mutated JAK1 in U4C cells was also able to restore sIL-R/IL-6-mediated STAT3 
phosphorylation, but the ability of A769662 to inhibit this effect was lost despite maintaining its 
ability to activate AMPK as measured by ACC phosphorylation (Figure 5B). 
We then examined the effects of AMPK activation on signaling downstream of a constitutively 
active Val658Phe-mutated version of JAK1 found in patients with acute lymphoblastic leukemia 
(ALL) (49). Analogous to the Val617Phe mutation in JAK2 responsible for several 
myeloproliferative neoplasms, this mutation within the JAK1 JH2 pseudokinase domain is 
thought to relieve an auto-inhibitory interaction with the catalytic JH1 domain, thereby 
increasing Tyr kinase activity independent of cytokine stimulation (1)(50). In contrast to WT 
JAK1, transient expression of Val658Phe JAK1 in JAK1-null U4C cells was sufficient to trigger 
detectable Tyr phosphorylation of both STAT1 and STAT3 in the absence of added cytokine 
(Figure 5C). Importantly, treatment with A769662 increased ACC phosphorylation and inhibited 
STAT1 and STAT3 Tyr phosphorylation. Expression of Val658Phe JAK1 incorporating the 
Ser515,518Ala (SSAA) mutations also resulted in increased basal STAT phosphorylation, 
although this was less than with Val658Phe JAK1. However, A769662 treatment failed to 
significantly inhibit the response despite increasing ACC phosphorylation (Figure 5C). Together, 
these observations suggest that Ser515 and Ser518 are required for effective AMPK-mediated 
inhibition of JAK1-mediated downstream signaling to STAT1 and STAT3. 
 
Discussion 
It is becoming increasingly apparent that cells can couple inflammatory status to the availability 
of nutrients (51)(52). Conversely, the mechanisms by which nutrient availability can regulate 
inflammation remain unclear. In this study we demonstrate that direct phosphorylation of JAK1, 
a key signaling intermediate utilized by a variety of cytokines, can occur in response to 
stimulation of AMPK, a key determinant of cellular energy status, by multiple activators. In 
conjunction with other observations, this would suggest that energy stress triggers an LKB1-
dependent activation of AMPK that can inhibit the JAK-STAT pathway via several distinct 
mechanisms. For example, others have shown that chronic AMPK activation in hepatocytes with 
metformin for 12 hr is able to increase levels of the orphan nuclear receptor small heterodimer 
partner (SHP), which reduces STAT3 phosphorylation on Tyr705 and co-localizes with nuclear 
STAT3 to reduce its binding to target gene promoters (53)(54). Similarly, others have 
demonstrated that chronic treatment of hepatocytes with AICAR suppresses IL-6 signaling, and  
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was thought to involve an AMPK-mediated inhibition of IL-6-stimulated Tyr phosphorylation 
and activation of JAK1 and JAK2, and that depletion of AMPK1 and 2 subunits could block 
the inhibitory effects of AMPK activators on cytokine-stimulated signaling without significantly 
altering basal activation (55)(56). However the underlying mechanisms were not investigated. 
Finally, a role for AMPK-mediated induction of mitogen-activated protein kinase phosphatase-1 
(MKP-1) has been reported to play a critical role in suppressing STAT1 activation in aortic 
smooth muscle cells (57). In contrast, we have demonstrated that AMPK-mediated 
phosphorylation of JAK1 within its regulatory SH2 domain is a rapid event mediated by direct 
AMPK activators (A769662, salicylate) and mitochondrial inhibitors (metformin) and is required 
for AMPK to inhibit STAT3 activation by IL-6 in multiple cell systems. The location of the 
conserved Ser518 residue at the start of the B helix within the JAK1 SH2 domain (39) suggests 
that phosphorylation may disrupt SH2 domain structure sufficiently to uncouple cytokine 
receptors from JAK1 activation, although this has yet to be tested. We also found that either 
AMPK1 knockdown or AV-mediated expression of dominant negative AMPK1 specifically 
blocked the ability of AMPK activators to suppress STAT, thereby ruling out a constitutive 
suppressive effect of AMPK on JAK-STAT signaling under our conditions. Finally, the 
existence of several inhibitory mechanisms by which AMPK can control JAK-STAT signaling 
mirrors the multi-faceted impact of AMPK on the mTOR signaling pathway, which it controls 
via direct phosphorylation of two components (TSC2 on Ser1387 (58)(59), Raptor on Ser722 and 
Ser792 (38)). These observations suggest that, like the mTOR pathway, AMPK-mediated 
regulation of JAK-STAT signaling has also evolved such that multiple mechanisms and targets 
are used to limit its activation. 
Given the importance of AMPK and JAK-STAT signaling pathways in controlling processes 
such as cell proliferation, longevity, angiogenesis and inflammation, AMPK-mediated JAK1 
phosphorylation could potentially influence these events. Several studies have reported that 
LKB1, the major kinase responsible for activation loop phosphorylation of AMPK subunits in 
response to energy stress, exerts a suppressive effect on STAT3 phosphorylation and function, 
such that loss of LKB1 increases STAT3 phosphorylation (60)(61)(62). LKB1 is a tumor 
suppressor and is frequently inactivated in human cancers (63), while hyperactivation of STAT3 
within tumor cells and the tumor microenvironment has been extensively described (18). The 
identification of JAK1 as a target would suggest that AMPK activation might be a useful strategy 
for limiting STAT3-mediated tumor progression, in addition to its well described effects on cell 
growth, proliferation and autophagy (45)(38)(64). The ability of AMPK to inhibit STAT 
phosphorylation following expression of a constitutively active Val658Phe-mutant of JAK1 via a 
mechanism requiring Ser515/518 would also support clinical studies to evaluate AMPK 
activators such as metformin as potential treatment options for ALL caused by activating JAK1 
mutations (49)(65). 
 
Materials and Methods 
Materials 
Antibodies against JAK1 were from BD Transduction Laboratories [cat. no. 610232]. HRP-
conjugated anti-GST antibodies were from Abcam [cat. no. ab3416]. Cytokines and HRP-
conjugated 14-3-3 were from R&D Systems. Other antibodies used have been described 
elsewhere (66)(67)(68)(21)(69). Peptide arrays were synthesized on glass slides by automatic 
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SPOT synthesis using Fmoc (9-fluorenylmethyloxycarbonyl) chemistry with the AutoSpot-
Robot ASS 222 [Intavis Bioanalytical Instruments]. AMPK preparations used for in vitro kinase 
assays were purified from rat liver as previously described (35). Ad5 adenoviruses expressing 
either GFP (AV.GFP) or a dominant negative mutant AMPKα1 (AV.DN-AMPK1) were 
prepared, titered and used to infect HUVECs as described previously(28)(68)(70) 
Cell culture and transfections 
SV40-immortalised WT and AMPK1-/-2-/- MEFs, HUVECs, U937 promonocytic cells and the 
human fibrosarcoma cell lines 2C4, U4C and U4C.JAK1 were cultured as previously described 
(34)(47)(48)(21)(71). Transient expression of WT and mutated JAK1 constructs in U4C cells 
was performed using PolyFect transfection reagent [Qiagen] in accordance with the 
manufacturer’s instructions. Transfection of HUVECs with siRNAs was performed as we have 
previously described (71)(72). 
Expression constructs 
pGEX4T/14-3-3 was obtained from Professor Graeme Milligan (University of Glasgow, UK). 
C-terminally Flag- and myc epitope-tagged human JAK1 in pCMV6 was obtained from Origene 
[cat. no. RC213878]. QuikChange mutagenesis [Agilent Technologies] was used to introduce 
JAK1 mutations at Ser515/518 to Ala, and Val658 to Phe. All constructs were sequenced in their 
entirety to ensure that no additional unanticipated mutations had been introduced. 
SDS-PAGE, immunoblotting and overlays 
Cells were washed twice with ice-cold PBS and lysed by scraping into lysis buffer (50 mM 
HEPES pH 7.4, 150 mM sodium chloride, 1% (v/v) Triton X-100, 0.5% (v/v) sodium 
deoxycholate, 0.1% (w/v) SDS, 10 mM sodium fluoride, 5mM EDTA, 10 mM sodium 
phosphate, 0.1 mM phenylmethylsulfonyl fluoride (PMSF), 10 μg/ml benzamidine, 10 μg/ml 
soybean trypsin inhibitor, 2% (w/v) EDTA-free complete protease inhibitor cocktail [Sigma]). 
After 30 min on ice, lysates were vortexed and cleared by centrifugation.  Equivalent amounts of 
protein, as determined by bicinchoninic acid protein assay, were fractionated by 8 to 12% SDS-
PAGE gels depending on the application, transferred to a nitrocellulose membrane and analyzed 
either by immunoblotting or overlay with HRP-14-3-3 as previously described (68)(71). Peptide 
arrays were blocked in 5% (w/v) BSA in Tris-buffered saline containing 0.1% (v/v) Tween-20 
(TBST) prior to overlay with HRP-14-3-3ζ (1:500 in BSA/TBST) overnight at 4oC, washing and 
visualization by enhanced chemiluminescence. 
Peptide array AMPK assays 
Peptide arrays were synthesized as previously described (73) AMPK phosphorylation of 
immobilized peptide arrays spotted in duplicate was undertaken with either vehicle or 0.5 
units/ml of purified rat liver AMPK (35) diluted in phosphorylation buffer (50 mM HEPES, 
pH7.4, 0.01% (v/v) Brij-35, 1 mM DTT, 1 mM ATP, 0.2 mM AMP, 25 mM MgCl2, 1% (w/v) 
BSA) containing 1 Ci [32P]ATP followed by incubation at 30°C for 30 min. Phosphorylated 
peptides were visualized by autoradiography. 
Pull-down assays and immunoprecipitations 
Recombinant GST, GST/14-3-3 and GST/14-3-3 were produced following induction in E. coli 
BL21 cells and purified from clarified bacterial extracts using glutathione-Sepharose beads. 20 
g of GST, GST/14-3-3 or GST/14-3-3 immobilized on glutathione-Sepharose beads were 
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added to protein-equalized clarified cell extracts prepared in pull down assay buffer (50 mM 
HEPES, pH 7.4, 120 mM NaCl, 5 mM EDTA, 10% (v/v) glycerol, 1% (v/v) Triton X-100, 
supplemented with phosphatase inhibitors 5mM sodium fluoride, 1mM sodium orthovanadate, 
and protease inhibitors 10 μg/ml benzamidine, 0.1mM PMSF, 10 μg/ml soybean trypsin 
inhibitor, 2% (w/v) EDTA-free complete protease inhibitor cocktail) and incubated overnight 
with rotation at 4oC. After washing three times in pull down assay buffer, samples were eluted in 
SDS-PAGE sample buffer by incubation at 65oC for 30 min prior to fractionation on 8% SDS-
PAGE gels and immunoblotting with anti-JAK1 antibody. GST fusion proteins were identified 
either by probing with HRP-conjugated anti-GST or Ponceau staining of nitrocellulose blots. 
Flag-tagged WT and mutated human JAK1 were immunoprecipitated from transfected U4C cells 
solubilized in immunoprecipitation buffer using Flag M2-Sepharose beads prior to analysis by 
SDS-PAGE and immunoblotting as previously described (73).  
Analysis of conditioned medium for chemotactic activity 
Conditioned medium was obtained from HUVECs pre-incubated in the presence or absence of 
100 M A769662 for 30 min prior to incubation with 25 ng/ml sIL-6R and 5 ng/ml IL-6 for 2 
h. HUVECs were washed prior to collection of conditioned medium for 1h (such that residual 
sIL-6R/IL-6 and A769662 were not in conditioned medium). Conditioned medium from each 
treatment was then added to the bottom wells of a Boyden chamber and equal numbers of U937 
promonocytic cells added to the top chamber, which was separated from the bottom by a 
collagen-coated membrane. After 5 hr, migrated U937 cells were collected from the lower well 
and counted in urinalysis glasstic slides [Stratagene, Cambridge, UK]. 
Statistical Analysis 
Results are expressed as mean ± SEM. Statistically significant differences were determined using 
a two-tail t-test, or one or two-way ANOVA where appropriate, with p < 0.05 as significant. 
 
Supplementary Materials 
Fig. S1. AMPK-dependence of inhibition of STAT3 phosphorylation in HUVECs. 
Fig. S2. AMPK inhibition of sIL-6R/IL-6-stimulated SOCS3 and CEBPD mRNA induction. 
Fig. S3. Contributions of JAK1, JAK2 and Tyk2 in mediating sIL-6R/IL-6-mediated STAT3 
phosphorylation in HUVECs. 
Fig. S4. Specific interaction of JAK1 with 14-3-3and 
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Fig. 1. AMPK rapidly inhibits IL-6 signaling and function. (A) HUVECs were pre-incubated 
in the presence or absence of 1 mM AICAR (2 hr), 100 μM A769662 (40 min) or a 
combination of 3 mM metformin and 5 mM salicylate (Met+Sal, 1 hr) prior to 
stimulation with sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 min as indicated. 
Protein-equalized cell lysates were then analyzed by SDS-PAGE and immunoblotting 
with the indicated antibodies. Densitometric analysis for STAT3 phosphorylation 
normalized to respective total levels is shown in each case. Data are shown as mean 
±SEM for N=3 independent experiments. **p<0.01, *p<0.05. (B) HUVECs were 
transfected with either non-targeting control or AMPK1-specific siRNAs as indicated.  
Cells were then pre-incubated in the presence or absence of 100 μM A769662 (40 min) 
prior to stimulation with sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 min as 
indicated. Protein-equalized cell lysates were then analyzed by SDS-PAGE and 
immunoblotting with the indicated antibodies. Densitometric analysis for STAT3 
phosphorylation normalized to respective total levels is shown in each case. Data are 
shown as mean ±SEM for N=3 independent experiments. *p<0.05. (C) HUVECs were 
pre-treated for 40 min with or without A769662 (100 M) prior to stimulation with sIL-
6R/IL-6 (25 ng/ml, 5 ng/ml) for 5 hr. Cell lysates were then analyzed by SDS-PAGE 
and immunoblotting with the indicated antibodies. Densitometric analysis of N=3 
independent experiments for SOCS3 and C/EBP normalized to GAPDH levels is shown. 
*p<0.05. (C) HUVECs were pre-treated for 30 min with or without A769662 (100 M) 
prior to stimulation with sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for 2 hr. After washing and 
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incubation in fresh medium for a further 1 hr, conditioned medium was removed and 
used for chemotaxis assays using U937 promonocytic cells. Data are shown as mean 
±SEM for N=3 independent experiments. *p<0.05. 
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Fig. 2. AMPK inhibits STAT1 and STAT3 activation by IL-6, LIF, OSM and IFN. (A) 
HUVECs were incubated for 30 min with either vehicle (V) or A769662 (100 M) prior 
to stimulation with either vehicle (-), sIL-6R/IL-6 (25 ng/ml, 5 ng/ml), leukemia 
inhibitory factor (LIF: 10 ng/ml) or oncostatin M (OSM: 10 ng/ml) for 30 min. Cell 
lysates were then analyzed by SDS-PAGE and immunoblotting with the indicated 
antibodies. Densitometric analysis for STAT1 and STAT3 phosphorylation at the 
indicated sites normalized to respective total levels is shown in each case. Data are shown 
as mean ±SEM for N=4 independent experiments. **p<0.001. *p<0.01. (B) HUVECs 
were incubated for 30 min with either vehicle (V) or A769662 (100 M) prior to 
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stimulation with either vehicle (V), sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for 30 min or IFN 
(1000U/ml) for 15 min. Cell lysates were then analyzed by SDS-PAGE and 
immunoblotting with the indicated antibodies. Densitometric analysis for STAT3 
phosphorylation normalized to respective total levels is shown in each case. Data are 
shown as mean ±SEM for N=3 independent experiments. *p<0.001. 
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Fig. 3. Identification of Ser515 and Ser518 within the JAK1 SH2 domain as sites of AMPK 
phosphorylation in vitro (A) Overlapping peptide arrays spanning the human JAK1 
open reading frame were subject to phosphorylation following incubation with [-
32P]ATP in the absence (-) or presence (+) of purified rat liver AMPK. The region of the 
array in which AMPK-dependent phosphorylation was detectable versus the no kinase 
control, and the location of the sequence within the domain structure of JAK1, is shown. 
Phosphorylation of immobilized SAMS peptide on the same array is also shown for 
comparison. This is representative of three experiments. (B) Immobilized peptides 
comprising WT and Ser/Ala-mutated versions of the indicated JAK1 sequence were 
subject to phosphorylation with [-32P]ATP in either the absence (-) or presence (+) of 
purified AMPK as described in panel A. Peptides in italics are those which displayed no 
detectable phosphorylation above parallel arrays incubated without purified AMPK. The 
positions of Ser515 and Ser 518 are indicated by asterisks (*) This is representative of 
three experiments. (C) Optimal and secondary selections for AMPK substrate recognition 
taken from ref. 38. The sequence from rat ACC1 known to be phosphorylated by AMPK 
at Ser79 is shown for comparison. The conformity of the sequence surrounding Ser518 
on human JAK1 to the AMPK consensus, and its evolutionary conservation, are shown. 
The sequence surrounding the Ser515 site on human JAK1 is also shown. The underlined 
Ser residue (equivalent to Ser518) indicates that this sequence would potentially conform 
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to a weak AMPK consensus site following the acquisition of negative charge upon its 
phosphorylation. (D) Upper: Alignment of SH2 domains from the four human JAK 
isoforms was performed using T-Coffee before being modified to match the structural 
data available for JAK1, JAK2 and Tyk2 (39–41).  For clarity, only the alignment of the 
indicated regions within each SH2 domain is shown. The lettering above the alignment 
indicates secondary structural elements, including the G1 and G2 regions present in 
the JAK2 and Tyk2 SH2 domains which are moderately disordered in the only available 
JAK1 SH2 domain structure (39). The residues corresponding to Ser515 and 518 in JAK1 
are underlined in bold, and the conserved Ser residues in JAK2, JAK3 and Tyk2 
equivalent to Ser518 are in bold and highlighted underneath with an asterisk (*). 
Residues in the boxed region highlighting sequences surrounding the conserved Ser 
residue in each JAK isoform are color coded similar to Panel C to show conformity to the 
AMPK consensus. Lower: The right hand figure shows the structure of the human JAK1 
FERM-SH2 fusion (PDB: 5IXD) generated using PyMol (39). The enlarged SH2 domain 
structure on the left hand side shows the location of Ser518 within the B helix 
immediately downstream of the EF loop.  The A loop present in all SH2 domains is also 
indicated. 
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Fig. 4 AMPK-mediated phosphorylation of JAK1 in intact cells. (A) Immobilized peptides 
comprising the indicated JAK1 sequence and variants with phosphorylated and non-
phosphorylated versions of Ser515 and Ser518 were overlaid with HRP-conjugated 14-3-
3 as indicated. Positive and negative control peptides for 14-3-3 interaction (74) are 
also shown. This is representative of N=3 experiments. (B) JAK1-null U4C human 
fibrosarcoma cells were transiently transfected with WT JAK1 or Ser515,518Ala (SSAA) 
JAK1 constructs versus a control transfection (Control) and treated with or without 
A769662 (100 M) for 40 min as indicated. 10% of each total cell extract was used for 
immunoblotting with the indicated antibodies. The remainder was incubated with 
GST/14-3-3 and glutathione-Sepharose beads. Captured JAK1 was detected by 
immunoblotting with anti-JAK1 antibody as indicated. Densitometric analysis for JAK1 
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pull down normalized to respective total levels is shown in each case. Data are shown as 
mean ±SEM for N=3 independent experiments. **p<0.01, *p<0.05. (C) Immortalized 
WT and AMPK1-/-2-/- MEFs were treated with A769662 (100 M) for the indicated 
times. 10% of each total extract was used for immunoblotting with the indicated 
antibodies. The remainder was incubated with GST/14-3-3 and glutathione-Sepharose 
beads. Captured endogenous JAK1 was detected by immunoblotting with anti-JAK1 
antibody as indicated. Densitometric analysis for JAK1 pull down normalized to 
respective total levels is shown in each case. Data are shown as mean ±SEM for N=3 
independent experiments. *p<0.05. (D) HUVECs were treated for the indicated times 
with metformin (3 mM) and salicylate (5 mM) (Met+Sal). 10% of each total extract was 
used for immunoblotting with the indicated antibodies. The remainder was incubated 
with GST/14-3-3 and glutathione-Sepharose beads. Captured JAK1 was detected by 
immunoblotting with anti-JAK1 antibody as indicated. Densitometric analysis of N=3 
independent experiments for JAK1 pull down normalized to respective total levels in 
each condition is shown. *p<0.05. 
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Fig. 5 AMPK-mediated inhibition of JAK1-dependent signaling requires Ser515 and 
Ser518. (A) JAK1-null U4C cells were transiently transfected with either control GFP or 
WT JAK1 constructs and treated with or without sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for 
30 min following a pre-incubation with or without A769662 (100 M) for 40 min as 
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indicated. Protein-equalized cell lysates were then analyzed by SDS-PAGE and 
immunoblotting with the indicated antibodies. This is representative of N=4 experiments. 
(B) U4C cells were transiently transfected with either WT JAK1 or Ser515,518Ala 
(SSAA) JAK1 constructs and treated with or without sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) 
for 30 min following a pre-incubation with or without A769662 (100 M) for 30 min as 
indicated. Protein-equalized cell lysates were then analyzed by SDS-PAGE and 
immunoblotting with the indicated antibodies. The dotted line indicates where unrelated 
lanes were removed for clarity. Densitometric analysis of STAT3 phosphorylation 
normalized to respective total levels is shown in each case. Data are shown as mean 
±SEM for N=3 independent experiments. *p<0.001. (C) U4C cells were transiently 
transfected with either WT JAK1, Val658Phe JAK1 (V658F) or Ser515,518Ala 
Val658Phe JAK1 (V658F SSAA) constructs prior to treatment with or without A769662 
(100 M) for 30 min as indicated. Protein-equalized cell lysates were then analyzed by 
SDS-PAGE and immunoblotting with the indicated antibodies. Densitometric analysis of 
STAT1 phosphorylation normalized to respective total levels is shown in each case. Data 
are shown as mean ±SEM for N=3 independent experiments. *p<0.01. 
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Fig. S1 AMPK-dependence of inhibition of STAT3 phosphorylation in HUVECs. (A) 
HUVECs were infected with control (GFP) or DN-AMPK1-expressing adenovirus 
(AV)  prior to treatment with or without sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for 30 min 
following a pre-incubation with or without A769662 (100 M) for 40 min as indicated.. 
Protein-equalized cell lysates were then analyzed by SDS-PAGE and immunoblotting 
with the indicated antibodies. The immunoblots shown are representative of multiple 
experiments. (B) HUVECs were pre-incubated in the presence or absence of 1 mM 
AICAR (2 hr) prior to stimulation with sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for a further 30 
min as indicated. Protein-equalized cell lysates were then analyzed by SDS-PAGE and 
immunoblotting with the indicated antibodies. The data shown are representative of 
multiple experiments. 
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Fig. S2. AMPK inhibition of sIL-6R/IL-6-mediated SOCS3 and CEBPD mRNA 
induction. HUVECs were pre-treated for 30 min with or without A769662 (100 M) 
prior to stimulation with sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for either 1 hr (CEBPD) or 3 
hr (SOCS3). Messenger RNA levels were then analyzed by quantitative reverse 
transcription PCR and normalized to GAPDH mRNA. Analysis of N=3 (CEBPD) or N=4 
(SOCS3) independent experiments for SOCS3 and CEBPD normalized to GAPDH levels 
is shown. For the CEBPD graph, *p<0.01, **p<0.001. For the SOCS3 graph, *p<0.001. 
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Fig. S3. Contributions of JAK1, JAK2 and Tyk2 towards mediating sIL-6R/IL-6-
mediated STAT3 phosphorylation in HUVECs. (A) HUVECs were transfected with 
either control or JAK isoform-targeted siRNAs as indicated prior to stimulation with or 
without sIL-6R/IL-6 (25 ng/ml, 5 ng/ml) for 30 min. Protein-equalized cell lysates were 
then analyzed by SDS-PAGE and immunoblotting with the indicated antibodies. The 
dotted lines indicate where unrelated lanes were removed for clarity. Densitometric 
analysis for inhibition of sIL-6R/IL-6-stimulated STAT3 phosphorylation normalized to 
respective total levels are shown for each of JAK1, JAK2 and Tyk2. Data are shown as 
mean ±SEM for N=3 (Tyk2), N=4 (JAK2) or N=5 (JAK1) independent experiments. 
**p<0.001, *p<0.01. 
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Fig. S4. Specific interaction of JAK1 with 14-3-3andJAK1-null U4C cells in 
which JAK1 was stably re-expressed were lysed and protein-equalized soluble extracts 
incubated with either GST or GST/14-3-3 and glutathione-Sepharose beads. Captured 
JAK1 and total JAK1 present in 10% of the total extracts used for the pull down assay 
were detected by immunoblotting with anti-JAK1 antibody, while recovered GST and 
GST/14-3-3 were identified by HRP-conjugated anti-GST as indicated. The data shown 
are representative of multiple experiments. (B) JAK1-null U4C cells in which JAK1 was 
stably re-expressed were lysed and protein-equalized soluble extracts incubated with 
either GST, GST/14-3-3 or GST/14-3-3 and glutathione-Sepharose beads. Captured 
JAK1 was detected by immunoblotting with anti-JAK1 antibody, while recovered GST 
fusion proteins were identified by HRP-conjugated anti-GST as indicated. The data 
shown are representative of multiple experiments. (C) U4C cells transiently transfected 
with either WT JAK1 or Ser515,518Ala (SSAA) JAK1 constructs were lysed and 
protein-equalized soluble extracts incubated with anti-Flag antibody to 
immunoprecipitate recombinant JAK1. Immunoprecipitates were probed with HRP-
conjugated 14-3-3 then re-probed with anti-JAK1 antibody as indicated. The data shown 
are representative of multiple experiments. 
